PD-L1 Immunohistochemistry Assays Show Comparable Results
PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
IASLC 2016
Durvalumab Shows Durable Response in Metastatic NSCLC
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC
Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).
Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC
First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).
Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control
Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.
Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC
Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.
Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC
Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).
The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health
The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.
Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases
Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).
Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer
Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in IASLC 2016
Loading... 
Loading...